All Stories

  1. Companion vaccines for CAR T-cell therapy: applying basic immunology to enhance therapeutic efficacy
  2. Silencing the intestinal GUCY2C tumor suppressor axis requires APC loss of heterozygosity
  3. Mobilizing Toxins for Cancer Treatment: Historical Perspectives and Current Strategies
  4. Talkin’ Toxins: From Coley’s to Modern Cancer Immunotherapy
  5. APC-β-catenin-TCF signaling silences the intestinal guanylin-GUCY2C tumor suppressor axis
  6. Adenovirus-Mediated ABCC6 Gene Therapy for Heritable Ectopic Mineralization Disorders
  7. Silencing the GUCA2A-GUCY2C tumor suppressor axis in CIN, serrated, and MSI colorectal neoplasia
  8. Therapeutic targeting of gastrointestinal cancer stem cells
  9. Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients
  10. TCR Retrogenic Mice as a Model To Map Self-Tolerance Mechanisms to the Cancer Mucosa Antigen GUCY2C
  11. Advances in Chimeric Antigen Receptor T-Cell Therapies for Solid Tumors
  12. Listeria monocytogenes as a Vector for Cancer Immunotherapy: Current Understanding and Progress
  13. Non-thermal plasma induces immunogenic cell death in vivo in murine CT26 colorectal tumors
  14. Human GUCY2C-targeted chimeric antigen receptor (CAR)-expressing T cells eliminate colorectal cancer metastases
  15. Immunotherapy regimens for metastatic colorectal carcinomas
  16. GUCY2C maintains intestinal LGR5+ stem cells by opposing ER stress
  17. The Heat-Stable Enterotoxin Receptor, Guanylyl Cyclase C, as a Pharmacological Target in Colorectal Cancer Immunotherapy: A Bench-to-Bedside Current Report
  18. GUCY2C Signaling Opposes the Acute Radiation-Induced GI Syndrome
  19. ST-Producing E. coli Oppose Carcinogen-Induced Colorectal Tumorigenesis in Mice
  20. Immunotherapy in Colorectal Cancer: Where Are We Now?
  21. The swinging pendulum of cancer immunotherapy personalization
  22. Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer
  23. Prime-Boost Immunization Eliminates Metastatic Colorectal Cancer by Producing High-Avidity Effector CD8 + T Cells
  24. siRNA-Encapsulated Hybrid Nanoparticles Target Mutant K- ras and Inhibit Metastatic Tumor Burden in a Mouse Model of Lung Cancer
  25. RB Loss Promotes Prostate Cancer Metastasis
  26. Preclinical Evaluation of a Replication-Deficient Recombinant Adenovirus Serotype 5 Vaccine Expressing Guanylate Cyclase C and the PADRE T-helper Epitope
  27. GUCY2C-directed CAR-T cells oppose colorectal cancer metastases without autoimmunity
  28. Intestinal Enteroids Model Guanylate Cyclase C-Dependent Secretion Induced by Heat-Stable Enterotoxins
  29. A novel role for Cish in the inhibition of TCR signaling
  30. Guanylyl Cyclase C Hormone Axis at the Intersection of Obesity and Colorectal Cancer
  31. Calorie-induced ER stress suppresses uroguanylin satiety signaling in diet-induced obesity
  32. Obesity-Induced Colorectal Cancer Is Driven by Caloric Silencing of the Guanylin-GUCY2C Paracrine Signaling Axis
  33. Targeting guanylate cyclase C in colorectal cancer: Where are we now?
  34. Biodistribution and Pharmacokinetics Study of siRNA-loaded Anti-NTSR1-mAb-functionalized Novel Hybrid Nanoparticles in a Metastatic Orthotopic Murine Lung Cancer Model
  35. Comparative Evaluation of Veriflow® Listeria monocytogenes to USDA and AOAC Culture Based Methods for the Detection of Listeria monocytogenes in Food
  36. DNA-PKcs-Mediated Transcriptional Regulation Drives Prostate Cancer Progression and Metastasis
  37. CD19-Targeted Nanodelivery of Doxorubicin Enhances Therapeutic Efficacy in B-Cell Acute Lymphoblastic Leukemia
  38. Is Financial Literacy Necessary for Radiation Oncology Residents?
  39. Correction: A Novel CDX2 Isoform Regulates Alternative Splicing
  40. The Paracrine Hormone for the GUCY2C Tumor Suppressor, Guanylin, Is Universally Lost in Colorectal Cancer
  41. Could targeting T-helper cells aid the development of effective cancer vaccines?
  42. A Novel CDX2 Isoform Regulates Alternative Splicing
  43. Epithelial Immunization Induces Polyfunctional CD8+ T Cells and Optimal Mousepox Protection
  44. Selective antigen-specific CD4+T-cell, but not CD8+T- or B-cell, tolerance corrupts cancer immunotherapy
  45. Veriflow® Campylobacter
  46. Tumor Radiation Therapy Creates Therapeutic Vaccine Responses to the Colorectal Cancer Antigen GUCY2C
  47. Polyamine-Blocking Therapy Reverses Immunosuppression in the Tumor Microenvironment
  48. Intestinal GUCY2C Prevents TGF-  Secretion Coordinating Desmoplasia and Hyperproliferation in Colorectal Cancer
  49. Translating colorectal cancer prevention through the guanylyl cyclase C signaling axis
  50. Immunotherapeutic strategies to target prognostic and predictive markers of cancer
  51. GUCY2C Opposes Systemic Genotoxic Tumorigenesis by Regulating AKT-Dependent Intestinal Barrier Integrity
  52. Epitope-targeted cytotoxic T cells mediate lineage-specific antitumor efficacy induced by the cancer mucosa antigen GUCY2C
  53. GUCY2C-targeted cancer immunotherapy: past, present and future
  54. A uroguanylin-GUCY2C endocrine axis regulates feeding in mice
  55. Functional Macroautophagy Induction by Influenza A Virus without a Contribution to Major Histocompatibility Complex Class II-Restricted Presentation
  56. Bacterial Heat-Stable Enterotoxins: Translation of Pathogenic Peptides into Novel Targeted Diagnostics and Therapeutics
  57. The Hormone Receptor GUCY2C Suppresses Intestinal Tumor Formation by Inhibiting AKT Signaling
  58. Bile Acids Initiate Lineage-Addicted Gastroesophageal Tumorigenesis by Suppressing the EGF Receptor-AKT Axis
  59. Lineage-Specific T-Cell Responses to Cancer Mucosa Antigen Oppose Systemic Metastases without Mucosal Inflammatory Disease
  60. Guanylyl cyclase C as a biomarker for targeted imaging and therapy of metastatic colorectal cancer
  61. Cytokine Adjuvanation of Therapeutic Anti-tumor Immunity Targeted to Cancer Mucosa Antigens
  62. Colorectal Cancer Is a Paracrine Deficiency Syndrome Amenable to Oral Hormone Replacement Therapy
  63. Guanylyl Cyclase C-Induced Immunotherapeutic Responses Opposing Tumor Metastases Without Autoimmunity
  64. Derivation and Fluidity of Acutely Induced Dysfunctional CD8+ T Cells
  65. Cancer Mucosa Antigens as a Novel Immunotherapeutic Class of Tumor-associated Antigen
  66. The Paracrine Hormone Hypothesis of Colorectal Cancer